Library Subscription: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Published 6 issues per year

ISSN Print: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Clinical Applications of Nanosized Drug-Delivery Systems in Lung Cancer Imaging and Therapy

Volume 37, Issue 5, 2020, pp. 435-471
DOI: 10.1615/CritRevTherDrugCarrierSyst.2020031657
Get accessGet access

ABSTRACT

Globally, lung cancer is one of the most frequently diagnosed and deadliest types of cancer. Lung cancer imaging can be performed using both invasive and noninvasive techniques, including magnetic resonance, positron emission tomography, single photon emission computed tomography, chest radiography, and computed tomography. But nonspecific contrast agents and radiopharmaceuticals are insufficient for early and specific diagnoses and imaging. In the case of lung cancer therapy, conventional therapeutic agents and radiotherapy may cause severe and systemic adverse and toxic effects and fail to eradicate all tumor tissue. Therefore, formulation of novel, targeted, and specific agents is critically important to overcome these challenges. In this review, we summarize lung cancer classification, current methods for lung cancer imaging and therapy, and future options containing nanosized systems for lung cancer imaging and/or therapy.

REFERENCES
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.

  2. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. In: Ahmad A, Gadgeel SM, editors. Lung cancer and personalized medicine: Current knowledge and therapies. Cham Heidelberg New York Dordrecht London: Springer International Publ. Switzerland; 2016. p. 1-19.

  3. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005 Sep 1;172(5):523-9.

  4. Comis RL. A brief history of the research and treatment of lung cancer from 1970 to 2003. Int J Clin Oncol. 2003 Aug;8(4):230-3.

  5. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I, WHO Panel. The 2015 World Health Organization classification of lung tumors' impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015 Sep;10(9):1243-60.

  6. Latimer KM, Mott TF. Lung cancer: Diagnosis, treatment principles, and screening. Am Fam Physician. 2015 Feb 15;91(4):250-6.

  7. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol. 2015 Jan;3(1):217-21.

  8. Travis W, Nicholson S, Hirsch FR, Pugatch B, Geisinger K, Brambilla E, Gazdar A, Petersen I, Meyerson M, Hanash SM, Jen J, Takahashi T, Fernandez EA, Capron F. Small cell carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 31-4.

  9. Hammar SP, Brambilla C, Pugatch B, Geisinger K, Fernandez EA, Vogt P, Petrovitchev N, Matsuno Y, Aisner S, Rami-Porta R, Capelozzi VL, Schmidt R, Carvalho L, Petersen I, Gazdar A, Meyerson M, Hanash SM, Jen J, Harris CC. Squamous cell carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 26-30.

  10. Colby TV, Noguchi M, Henschke C, Vazquez MF, Geisinger K, Yokose T, Ohori P, Rami-Porta R, Franks T, Shimosato Y, Matsuno Y, Khoor A, Westra WH, Jambhekar NA, Petersen I, Takahashi T, Kawai T, Meyerson M, Hanash SM, Jen J. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 35-44.

  11. Brambilla E, Pugatch B, Geisinger K, Gal A, Sheppard MN, Guinee DG, Jiang SX, Lantuejoul S, Chang YL, Petersen I, Meyerson M, Hanash SM, Noguchi M. Large cell carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 45-50.

  12. De Wever W, Verschakelen J, Coolen J. Role of imaging in diagnosis, staging and follow-up of lung cancer. Curr Opin Pulm Med. 2014 Jul;20(4):385-92.

  13. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer diagnosis and management of lung cancer. 3rd ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5):E142-65.

  14. Hyer JD, Silvestri G. Diagnosis and staging of lung cancer. Clin Chest Med. 2000 Mar;21(1):95-106.

  15. MacMahon H, Li F, Engelmann R, Roberts R, Armato S. Dual energy subtraction and temporal subtraction chest radiography. J Thorac Imag. 2008 May;23(2):77-85.

  16. Kim SM, Chung MJ, Lee KS, Kang H, Song IY, Lee EJ, Hwang HS. Digital tomosynthesis of the thorax: The influence of respiratory motion artifacts on lung nodule detection. Acta Radiol. 2013 Jul;54(6):634-9.

  17. Xiang D, Zhang B, Doll D, Shen K, Kloecker G, Freter C. Lung cancer screening: From imaging to biomarker. Biomark Res. 2013 Jan 16;1(1):4.

  18. Attia MF, Wallyn J, Anton N, Vandamme TF. Inorganic nanoparticles for X-ray computed tomography imaging. Crit Rev Ther Drug Carrier Syst. 2018;35(5):391-431.

  19. Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, Hasegawa M, Kawakami S, Kubo K, Haniuda M, Yamanda T. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer. 2001 Jan 5;84(1):25-32.

  20. Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M. Lung cancer screening, version 3.2018. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Apr;16(4):412-41.

  21. Walsh SL, Nair A, Hansell DM. Post-processing applications in thoracic computed tomography. Clin Radiol. 2013 May;68(5):433-48.

  22. Zhang LJ, Yang GF, Wu SY, Xu J, Lu GM, Schoepf UJ. Dual-energy CT imaging of thoracic malignancies. Cancer Imaging. 2013 Mar 6;13(1):81-91.

  23. Vardhanabhuti V, Loader RJ, Mitchell GR, Riordan RD, Roobottom CA. Image quality assessment of standard- and low-dose chest CT using filtered back projection, adaptive statistical iterative reconstruction, and novel model-based iterative reconstruction algorithms. Am J Roentgenol. 2013 Mar;200(3):545-52.

  24. Ma SH, Le HB, Jia BH, Wang ZX, Xiao ZW, Cheng XL, Mei W, Wu M, Hu ZG, Li YG. Peripheral pulmonary nodules: Relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer. 2008 Jun 30;8:186.

  25. Lee WK, Lau EW, Chin K, Sedlaczek O, Steinke K. Modern diagnostic and therapeutic interventional radiology in lung cancer. J Thorac Dis. 2013 Oct;5 Suppl 5:S511-23.

  26. Armato SG 3rd, Labby ZE, Coolen J, Klabatsa A, Feigen M, Persigehl T, Gill RR. Imaging in pleural mesothelioma: A review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer. 2013 Nov;82(2):190-6.

  27. Sommer G, Tremper J, Koenigkam-Santos M, Delorme S, Becker N, Biederer J, Kauczor HU, Heussel CP, Schlemmer HP, Puderbach M. Lung nodule detection in a high-risk population: Comparison of magnetic resonance imaging and low-dose computed tomography. Eur J Radiol. 2014 Mar;83(3):600-5.

  28. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiov Sur. 2001 Sep;122(3):548-53.

  29. Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, Choi JY, Chung MJ. Non-small cell lung cancer staging: Efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008 Aug;248(2):632-42.

  30. Hollings N, Shaw P. Diagnostic imaging of lung cancer. Eur Respir J. 2002 Apr;19(4):722-42.

  31. Hatabu H, Stock KW, Sher S, Edinburgh KJ, Levin DL, Garpestad E, Albert MS, Mai VM, Chen Q, Edelman RR. Magnetic resonance imaging of the thorax. Past, present, and future. Clin Chest Med. 1999 Dec;20(4):775-803.

  32. Karpuz M, Silindir-Gunay M, Ozer AY. Current and future approaches for effective cancer imaging and treatment. Cancer Biother Radio. 2018 Mar;33(2):39-51.

  33. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996 Jun;37(6):943-8.

  34. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman E, Wolfe WG. Lung-tumor growth correlates with glucose-metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995 Nov;60(5):1348-52.

  35. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions-a meta-analysis. J Am Med Assoc. 2001 Feb 21;285(7):914-24.

  36. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM, Onko-PET der Deutschen Gesellschaft fur Nuklearmedizin. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie. 2001 Aug;55(8):367-77.

  37. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology. 1999 Nov;213(2):530-6.

  38. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, Verschakelen JA. Additional value of PET-CT in the staging of lung cancer: Comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007 Jan;17(1):23-32.

  39. Sobic-Saranovic D, Pavlovic S, Jovanovic D, Neboisa K, Todorovic-Timanic M, Subotic D, Artiko V, Obradovic V. Assessment of non-small cell lung cancer viability and necrosis with three radiopharma-ceuticals. Hell J Nucl Med. 2008 Jan-Apr;11(1):16-20.

  40. Spanu A, Schillaci O, Pirina P, Arru A, Madeddu G, Chessa F, Marongiu P, Solinas ME, Madeddu G. 99mTc-Tetrofosmin SPECT in solitary pulmonary nodule evaluation. Oncol Rep. 2006 Oct;16(4):763-9.

  41. Blum JH, Hirsch H, Lister-James J, Rinne N, NeoTect Solitary Pulmonary Nodule Study Group. A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest. 2000 May;117(5):1232-8.

  42. Wang L, Yin X, Wang F, Gu J, Lu L, Wu Q, Shen B, Li XF. The usefulness of combined diagnostic CT and 99mTc-octreotide somatostatin receptor SPECT/CT imaging on pulmonary nodule characterization in patients. Cancer Biother Radiopharm. 2013 Dec;28(10):731-6.

  43. Nishiyama Y, Yamamoto Y, Satoh K, Ohkawa M, Kameyama K, Hayashi E, Fujita J, Tanabe M. Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin Nucl Med. 2000 May;25(5):364-9.

  44. Hennon MW, Demmy TL. Video-assisted thoracoscopic surgery (VATS) for locally advanced lung cancer. Ann Cardiothorac Surg. 2012 May;1(1):37-42.

  45. Wei S, Chen M, Chen N, Liu L. Feasibility and safety of robot-assisted thoracic surgery for lung lobectomy in patients with non-small cell lung cancer: A systematic review and meta-analysis. World J Surg Oncol. 2017 May 8;15(1):98.

  46. Parashar B, Arora S, Wernicke AG. Radiation therapy for early stage lung cancer. Semin Intervent Radiol. 2013 Jun;30(2):185-90.

  47. Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, Muacevic A, Mahadevan A. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch((R)) patient registry. Radiat Oncol. 2015 May 15;10:113.

  48. Skowronek J. Brachytherapy in the treatment of lung cancer-a valuable solution. J Contemp Brachyther. 2015 Aug;7(4):297-311.

  49. Goldberg M, Timotin E, Farrell T, Puksa S, Donde B, Sur R. A prospective analysis of high-dose-rate endobronchial brachytherapy in the palliation of obstructive symptoms in lung cancer patients: A single-institution experience. Brachytherapy. 2015 Sep-Oct;14(5):655-61.

  50. Huo X, Wang H, Yang J, Li X, Yan W, Huo B, Zheng G, Chai S, Wang J, Guan Z, Yu Z. Effectiveness and safety of CT-guided (125)I seed brachytherapy for postoperative locoregional recurrence in patients with non-small cell lung cancer. Brachytherapy. 2016 May-Jun;15(3):370-80.

  51. Yamamoto T, Kabus S, Bal M, Keall P, Benedict S, Daly M. The first patient treatment of computed tomography ventilation functional image-guided radiotherapy for lung cancer. Radiother Oncol. 2016 Feb;118(2):227-331.

  52. Baisi A, De Simone M, Raveglia F, Cioffi U. Thermal ablation in the treatment of lung cancer: Present and future. Eur J Cardiothorac Surg. 2013 Apr;43(4):683-6.

  53. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radio-frequency ablation of malignancies in the lung. Am J Roentgenol. 2000 Jan;174(1):57-9.

  54. Narsule CK, Sridhar P, Nair D, Gupta A, Oommen RG, Ebright MI, Litle VR, Fernando HC. Percutaneous thermal ablation for stage IA non-small cell lung cancer: Long-term follow-up. J Thorac Dis. 2017 0ct;9(10):4039-45.

  55. de Baere T, Auperin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussiere J. Radiofrequency ablation is a valid treatment option for lung metastases: Experience in 566 patients with 1037 metastases. Ann Oncol. 2015 May;26(5):987-91.

  56. de Baere T, Mahnken, AH. Radiofrequency ablation for treating malignant tumors to the lungs. In: Cutsem EV, Vogl TJ, Orsi F, Sobrero A, editors. Locoregional tumor therapy. Berlin, Heidelberg: Springer-Verlag; 2014. p. 235-42.

  57. Sidoff L, Dupuy DE. Clinical experiences with microwave thermal ablation of lung malignancies. Int J Hyperthermia. 2017 Feb;33(1):25-33.

  58. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: Principles and applications. Radiographics. 2005 Oct;25 Suppl 1:S69-83.

  59. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'Addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005 Oct 1;23(28):6854-64.

  60. Timmer-Bonte JNH, Punt CJA, vd Heijden HFM, van Die CE, Bussink J, Beijnen JH, Huitema ADR, Tjan-Heijnen VCG. Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung Cancer. 2008 May;60(2):222-30.

  61. Pirker R. EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target Oncol. 2013 Mar;8(1):47-53.

  62. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013 Jun 1;31(16):1997-2003.

  63. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006 Jan 30;94(2):259-67.

  64. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010 Dec 15;16(24):6132-8.

  65. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.

  66. Cui J, Cai X, Zhu M, Liu T, Zhao N. The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: A meta-analysis from 30 randomized controlled clinical trials. PLoS One. 2013;8(4):e62038.

  67. Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology. 2013 May 1;2(5):e24436.

  68. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multi-center phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54.

  69. Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol. 2013 Oct;14(11):1104-11.

  70. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54.

  71. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb;3(1):53-63.

  72. Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C. Immunotherapy in lung cancer: A new age in cancer treatment. Adv Exp Med Biol. 2018;995:65-95.

  73. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J Clin Oncol. 2013 Jul 1;31(19):2396-403.

  74. Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011 Nov 1;17(21):6847-57.

  75. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L, Scheinberg DA. WT1 Peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010 Oct;59(10):1467-79.

  76. Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opin Biol Ther. 2018 Jul;18(7):829-35.

  77. Lievense L, Aerts J, Hegmans, J. Immune therapy. In: Ahmad A, Gadgeel S, editors. Lung cancer and personalized medicine: Current knowledge and therapies. Cham Heidelberg New York Dordrecht London: Springer International Publ. Switzerland; 2016. p. 59-83.

  78. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94.

  79. Cafarotti S, Lococo F, Froesh P, Zappa F, Andre D. Target therapy in lung cancer. In: Ahmad A, Gadgeel S, editors. Lung cancer and personalized medicine: Current knowledge and therapies. Cham Heidelberg New York Dordrecht London: Springer International Publ. Switzerland; 2016. p. 127-36.

  80. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018 Mar;13(3):323-58.

  81. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8.

  82. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37.

  83. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213-22.

  84. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kolbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89.

  85. Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV. Afatinib therapy: Practical management of adverse events with an oral agent for non-small cell lung cancer treatment. Clin J Oncol Nurs. 2018 Oct 1;22(5):542-8.

  86. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629-40.

  87. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-25.

  88. Cheriyan VT, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I, Sau S, Muthu M, Polin LA, Levi E, Bepler G, Iyer AK, Singh M, Rishi AK. A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget. 2018 Jul 3;9(51):29680-97.

  89. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 2014 Feb;83(2):211-8.

  90. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.

  91. Ellis PM. Anti-angiogenesis in personalized therapy of lung cancer. In: Ahmad A, Gadgeel S, editors. Lung cancer and personalized medicine: Current knowledge and therapies. Cham Heidelberg New York Dordrecht London: Springer International Publ. Switzerland; 2016. p. 91-126.

  92. Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15;121(6):883-92.

  93. Gadgeel SM. Targeted therapy and immune therapy for small cell lung cancer. Curr Treat Options Oncol. 2018 Sep 10;19(11):53.

  94. Langer CJ, Albert I, Ross HJ, Kovacs P, Blakely LJ, Pajkos G, Somfay A, Zatloukal P, Kazarnowicz A, Moezi MM, Schreeder MT, Schnyder J, Ao-Baslock A, Pathak AK, Berger MS, GEM Investigators. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 2014 Sep;85(3):420-8.

  95. Kim ES. Chemotherapy resistance in lung cancer. In: Ahmad A, Gadgeel S, editors. Lung cancer and personalized medicine: Current knowledge and therapies. Cham Heidelberg New York Dordrecht London: Springer International Publ. Switzerland; 2016. p. 189-209.

  96. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995 Oct 7;311(7010):899-909.

  97. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol. 2003 Aug 15;21(16):3016-24.

  98. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.

  99. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 Jan 6;91(1):66-72.

  100. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V, MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter Italian Lung Cancer in the Elderly study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362-72.

  101. Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017 Jun 6;8(23):38022-43.

  102. Chougule M, Patel AR, Sachdeva P, Jackson T, Singh M. Anticancer activity of noscapine, an opioid alkaloid in combination with cisplatin in human non-small cell lung cancer. Lung Cancer. 2011 Mar;71(3):271-82.

  103. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res. 2009 Jan 15;15(2):543-52.

  104. Jones SF, Infante JR, Spigel DR, Peacock NW, Thompson DS, Greco FA, McCulloch W, Burris HA 3rd. Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Invest. 2012 Jul;30(6):481-6.

  105. Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GA. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol. 2013 Jan;71(1):115-21.

  106. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, Baylin SB, Brock MV, Rudin CM. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011 Dec;1(7):598-607.

  107. Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer Study Group trial 1001. J Thorac Oncol. 2015 Mar;10(3):486-91.

  108. Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2013 May;8(5):619-23.

  109. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2006 Feb 1;24(4):688-94.

  110. Baas P, Belderbos JS, van den Heuvel M. Chemoradiation therapy in nonsmall cell lung cancer. Curr Opin Oncol. 2011 Mar;23(2):140-9.

  111. O'Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010 Jun 16(6):CD002140.

  112. Glatzer M, Elicin O, Ramella S, Nestle U, Putora PM. Radio(chemo)therapy in locally advanced non-small cell lung cancer. Eur Respir Rev. 2016 Mar;25(139):65-70.

  113. Lecumberri R, Lopez Vivanco G, Font A, Gonzalez Billalabeitia E, Gurpide A, Gomez Codina J, Isla D, Galan A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. Thromb Res. 2013;132(6):666-70.

  114. Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10;29(17):2312-8.

  115. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul;18(7):895-903.

  116. Ready N, Janne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE, Cancer Leukemia Group B. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep;5(9):1382-90.

  117. Jose C, Amra K, Bhavsar C, Momin M, Omri A. Polymeric lipid hybrid nanoparticles: Properties and therapeutic applications. Crit Rev Ther Drug Carrier Syst. 2018;35(6):555-88.

  118. Pandey V, Kohli S. Lipids and surfactants: The inside story of lipid-based drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2018;35(2):99-155.

  119. Khan I, Gothwal A, Sharma AK, Kesharwani P, Gupta L, Iyer AK, Gupta U. PLGA nanoparticles and their versatile role in anticancer drug delivery. Crit Rev Ther Drug Carrier Syst. 2016;33(2):159-93.

  120. Dhas NL, Kudarha RR, Acharya NS, Acharya SR. Polymeric immunonanoparticles mediated cancer therapy: Versatile nanocarriers for cell-specific cargo delivery. Crit Rev Ther Drug Carrier Syst. 2018;35(1):1-64.

  121. Gharat SA, Momin M, Bhavsar C. Oral squamous cell carcinoma: Current treatment strategies and nanotechnology-based approaches for prevention and therapy. Crit Rev Ther Drug Carrier Syst. 2016;33(4):363-400.

  122. Bhosale RR, Gangadharappa HV, Gowda DV, Osmani R, Vaghela R, Kulkarni PK, Sairam KV, Gurupadayya B. Current perspectives on novel drug carrier systems and therapies for management of pancreatic cancer: An updated inclusive review. Crit Rev Ther Drug Carrier Syst. 2018;35(3):195-292.

  123. Ashfaq UA, Riaz M, Yasmeen E, Yousaf MZ. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment. Crit Rev Ther Drug Carrier Syst. 2017;34(4):317-53.

  124. Muntimadugu E, Kommineni N, Khan W. Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. Pharmacol Res. 2017 Dec;126:109-22.

  125. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: An updated review. Pharmaceutics. 2017 Mar 27;9(2):E12.

  126. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010;624:25-37.

  127. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010 Nov;7(11):653-64.

  128. Michiels C, Tellier C, Feron O. Cycling hypoxia: A key feature of the tumor microenvironment. Biochim Biophys Acta. 2016 Aug;1866(1):76-86.

  129. Miao L, Huang L. Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res. 2015;166:193-226.

  130. Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016 Dec 28;244(Pt A):108-21.

  131. Chang D, Gao Y, Wang L, Liu G, Chen Y, Wang T, Tao W, Mei L, Huang L, Zeng X. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy. J Colloid Interface Sci. 2016 Feb 1;463:279-87.

  132. Zhao Y, Fan X, Liu D, Wang Z. PEGylated thermo-sensitive poly(amidoamine) dendritic drug delivery systems. Int J Pharm. 2011 May 16;409(1-2):229-36.

  133. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target. 2003 Apr;11(3):139-49.

  134. Li B, Wang Q, Zou R, Liu X, Xu K, Li W, Hu J. Cu7.2S4 Nanocrystals: A novel photothermal agent with a 56.7% photothermal conversion efficiency for photothermal therapy of cancer cells. Nanoscale. 2014 Mar 21;6(6):3274-82.

  135. Wu J, Deng C, Meng F, Zhang J, Sun H, Zhong Z. Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. J Control Release. 2017 Aug 10;259:76-82.

  136. Xiong Y, Zhao Y, Miao L, Lin CM, Huang L. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release. 2016 Dec;244(Pt A):63-73.

  137. Singh RP, Sharma G, Sonali, Singh S, Patne SCU, Pandey BL, Koch B, Muthu MS. Effects of transferrin conjugated multi-walled carbon nanotubes in lung cancer delivery. Mater Sci Eng C Mater Biol Appl. 2016 Oct;67:313-325.

  138. Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm. 2014 Oct 20;474(1-2):112-22.

  139. Guo C, Al-Jamal WT, Toma FM, Bianco A, Prato M, Al-Jamal KT, Kostarelos K. Design of cationic multiwalled carbon nanotubes as efficient siRNA vectors for lung cancer xenograft eradication. Bioconjug Chem. 2015 Jul 15;26(7):1370-9.

  140. Feng C, Li X, Dong C, Zhang X, Zhang X, Gao Y. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: Evaluation of their effect in lung cancer. Drug Des Devel Ther. 2015;9:4613-20.

  141. Yung BC, Li J, Zhang M, Cheng X, Li H, Yung EM, Kang C, Cosby LE, Liu Y, Teng L, Lee RJ. Lipid nanoparticles composed of quaternary amine-tertiary amine cationic lipid combination (QTsome) for therapeutic delivery of anti-miR-21 for lung cancer. Mol Pharm. 2016 Feb 1;13(2):653-62.

  142. Cheng L, Huang FZ, Cheng LF, Zhu YQ, Hu Q, Li L, Wei L, Chen DW. GE11-modified liposomes for non-small cell lung cancer targeting: Preparation, ex vitro and in vivo evaluation. Int J Nanomed. 2014;9:921-35.

  143. Aqil F, Kausar H, Agrawal AK, Jeyabalan J, Kyakulaga AH, Munagala R, Gupta R. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol. 2016 Aug;101(1):12-21.

  144. Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, Sun MG, Shi JF, Zhang CX, Lu WL. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013 May;34(14):3626-38.

  145. Singh RP, Sharma G, Sonali, Singh S, Kumar M, Pandey BL, Koch B, Muthu MS. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016 May 1;141:429-42.

  146. Mandal B, Mittal NK, Balabathula P, Thoma LA, Wood GC. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer. Eur J Pharm Sci. 2016 Jan 1;81:162-71.

  147. Singh RP, Sharma G, Sonali, Singh S, Bharti S, Pandey BL, Koch B, Muthu MS. Chitosan-folate decorated carbon nanotubes for site specific lung cancer delivery. Mater Sci Eng C Mater Biol Appl. 2017 Aug 1;77:446-58.

  148. Ao L, Reichel D, Hu D, Jeong H, Kim KB, Bae Y, Lee W. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. J Pharmacol Exp Ther. 2015 Nov;355(2):168-73.

  149. Luo Y, Cai X, Li H, Lin Y, Du D. Hyaluronic acid-modified multifunctional Q-Graphene for targeted killing of drug-resistant lung cancer cells. ACS Appl Mater Interfaces. 2016 Feb 17;8(6):4048-55.

  150. Cai X, Luo Y, Zhang W, Du D, Lin Y. pH-sensitive ZnO quantum dots-doxorubicin nanoparticles for lung cancer targeted drug delivery. ACS Appl Mater Interfaces. 2016 Aug 31;8(34):22442-50.

  151. Wu YF, Wu HC, Kuan CH, Lin CJ, Wang LW, Chang CW, Wang TW. Multi-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapy. Sci Rep. 2016 Feb 16;6:21170.

  152. Minati L, Antonini V, Dalla Serra M, Speranza G. Multifunctional branched gold-carbon nanotube hybrid for cell imaging and drug delivery. Langmuir. 2012 Nov 13;28(45):15900-6.

  153. Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small. 2009 Aug 17;5(16):1862-8.

  154. Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials. 2013 Jan;34(2):470-80.

  155. Yoo MK, Park IK, Lim HT, Lee SJ, Jiang HL, Kim YK, Choi YJ, Cho MH, Cho CS. Folate-PEG-superparamagnetic iron oxide nanoparticles for lung cancer imaging. Acta Biomater. 2012 Aug;8(8):3005-13.

  156. Huang G, Zhang C, Li S, Khemtong C, Yang SG, Tian R, Minna JD, Brown KC, Gao J. A novel strategy for surface modification of superparamagnetic iron oxide nanoparticles for lung cancer imaging. J Mater Chem. 2009;19:6367-72.

  157. Liu Y, Ibricevic A, Cohen JA, Cohen JL, Gunsten SP, Frechet JM, Walter MJ, Welch MJ, Brody SL. Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm. 2009 Nov-Dec;6(6):1891-2.

  158. Li XT, Zhou ZY, Jiang Y, He ML, Jia LQ, Zhao L, Cheng L, Jia TZ. PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer. J Drug Target. 2015 Apr;23(3):232-43.

  159. Dou YN, Dunne M, Huang H, McKee T, Chang MC, Jaffray DA, Allen C. Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma. J Drug Target. 2016 Nov;24(9):865-77.

  160. Liu J, Cheng H, Han L, Qiang Z, Zhang X, Gao W, Zhao K, Song Y. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2018;12:3199-209.

  161. Xu C, Wang Y, Guo Z, Chen J, Lin L, Wu J, Tian H, Chen X. Pulmonary delivery by exploiting doxo- rubicin and cisplatin coloaded nanoparticles for metastatic lung cancer therapy. J Control Release. 2019 Feb 10;295:153-63.

  162. Zhang Q, Tian X, Cao X. Transferrin-functionalised microemulsion co-delivery of P-elemene and celastrol for enhanced antilung cancer treatment and reduced systemic toxicity. Drug Deliv Transl Res. 2019 Jun;9(3):667-78.

  163. Kelkar SS, Reineke TM. Theranostics: Combining imaging and therapy. Bioconjug Chem. 2011 Oct 19;22(10):1879-903.

  164. Navyatha B, Nara S. Theranostic nanostructures for ovarian cancer. Crit Rev Ther Drug Carrier Syst. 2019;36(4):305-71.

  165. Ren L, Chen S, Li H, Zhang Z, Ye C, Liu M, Zhou X. MRI-Visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies. Nanoscale. 2015 Aug;7(30):12843-50.

  166. Lin LT, Chang CH, Yu HL, Liu RS, Wang HE, Chiu SJ, Chen FD, Lee TW, Lee YJ. Evaluation of the therapeutic and diagnostic effects of PEGylated liposome-embedded 188Re on human non-small cell lung cancer using an orthotopic small-animal model. J Nucl Med. 2014 Nov;55(11):1864-70.

  167. Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, Lin MH, Wang HE. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorg Med Chem Lett. 2013 Jun;23(11):3180-5.

  168. Patel AR, Chougule MB, Lim E, Francis KP, Safe S, Singh M. Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomedicine. 2014 Jul;10(5):1053-63.

CITED BY
  1. Ezhilarasan Devaraj, Lakshmi Thangavelu, Mallineni Sreekanth Kumar, Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges, Nanomedicine, 2022. Crossref

  2. Karpuz Merve, İlhan Miray, Gültekin Hazal Ezgi, Ozgenc Emre, Şenyiğit Zeynep, Atlihan-Gundogdu Evren, Nanovesicles for tumor-targeted drug delivery, in Applications of Nanovesicular Drug Delivery, 2022. Crossref

  3. Li Tongtong, Zhou Tong, Liu Ying, Wang Jingyue, Yu Zhenxiang, Efficacy analysis of targeted nanodrug for non-small cell lung cancer therapy, Frontiers in Bioengineering and Biotechnology, 10, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain